Please use this identifier to cite or link to this item:
http://localhost:80/xmlui/handle/123456789/14045
Title: | Effect of azithromycin and pefloxacin in treatment of acute enteritis based on clinical efficacy comparison |
Authors: | Yang, Deying Zhao, Deqin Gong, Xufei Chen, Xinrui |
Keywords: | Azithromycin pefloxacin acute enteritis therapeutic effect comparative analysis |
Issue Date: | 20-Sep-2017 |
Publisher: | Karachi:Pakistan Journal of Pharmaceutical Sciences, university of Karachi. |
Citation: | Yang, D., Zhao, D., Gong, X., & Chen, X. (2017). Effect of azithromycin and pefloxacin in treatment of acute enteritis based on clinical efficacy comparison. Pakistan Journal of Pharmaceutical Sciences, 30. |
Abstract: | This paper aims to compare and analyze clinical efficacy of azithromycin and pefloxacin in treatment of acute enteritis. The 160 patients with acute enteritis were randomly divided into a study group (n=80) treated with azithromycin, and a reference group (n=80) treated with pefloxacin. We compared overall treatment efficiency (markedly, effective, invalid), clinical symptoms and signs remission time (antipyretic time, antidiarrheal time, symptoms and signs disappearance time), interleukin-6 and C-reactive protein concentration before and after treatment, adverse reactions rate (nausea, abdominal pain, headache, etc.). In comparison of overall treatment efficiency of the two groups, the results showed that the study group was significantly superior to the reference group (P<0.05). In comparison of clinical symptoms and signs remission time of the two groups, the study group were significantly shorter than the reference group (P<0.05). At the same time, in comparison of levels of interleukin-6 and C-reactive protein concentration after treatment, the study group was significantly superior to the reference group (P<0.05). There was no significant difference between the two groups in incidence of adverse reactions (P<0.05). The efficacy of azithromycin for acute enteritis is better than that of pefloxacin, and it can significantly reduce clinical symptom remission time. Moreover, safe and reliable, it has great value in clinical application. |
URI: | http://142.54.178.187:9060/xmlui/handle/123456789/14045 |
ISSN: | 1011-601X |
Appears in Collections: | No.5(Special), September, 2017 |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
5-SP-5870.htm | 192 B | HTML | View/Open |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.